Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070989 | 0.98 | SMN1; SMN2 (0.69) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL4068598 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL2834532 | 0.76 | MAPK1 (1.00) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL19392453 | 0.76 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL29259787 | 0.76 | ALDH1A1 (1.00) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL2916275 | 0.76 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL13846055 | 0.76 | MAPK1 (1.00) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL10082160 | 0.76 | MAPK1 (1.00) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL13845977 | 0.76 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL128274 | 0.76 | ALDH1A1 (1.00) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | SMN1; SMN2 3431/4885KDM4E 3083/4885RECQL 637/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | SMN1; SMN2 2771/4885KDM4E 3299/4885RECQL 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.